Hepatitis B Vaccine Delivered Trans-dermally by MAP

Summary

This is Phase I, randomized, open-label, active-controlled study to evaluate the safety, tolerability, and immunogenicity of a hepatitis B vaccine administered trans-dermally via microneedle array patch (MAP) compared to the intra-muscular (IM) hepatitis B vaccine (Euvax B™), administered at Day (D) 0, Week (W) 4, W26 among healthy adults aged 19 to 40 years in the Republic of Korea.

Timeline

Start

2025-02-05

Primary completion

2026-08-05

Completion

2026-11-05

Drugs

Indications